Contact a distributor

ATryn is available through the following authorized distributors. Please contact a vendor directly to place your order.

ABO Pharmaceuticals
7930 Arjons Drive, Suite A
San Diego, CA 92126
ASD Healthcare
3101 Gaylord Parkway, 3rd Floor
Frisco, TX 75034
BDI Pharma
120 Research Drive
Columbia, SC 29203
2826 South Potter Road
Tempe, AZ 85282
Bloodcenter of Wisconsin
638 N. 18th Street
Milwaukee, WI 53201
Cardinal Health SPD
305 Tech Park Drive
Suite 113
La Vergne, TN 37086
FFF Enterprises, Inc.
41093 County Center Drive
Temecula, CA 92591
McKesson Plasma and BioLogics, LLC
401 Mason Road
La Vergne, TN 37086
Prodigy Health Supplier
9417 Brodie Lane
Austin, TX 78748

Ready when you need it

  • ATryn is a sterile, lyophilized powder; each single-use vial contains the potency stated on the label, which is approximately 525 IU or 1750 IU1
  • Store ATryn refrigerated between 2°C and 8°C (36°F and 46°F)1

References: 1. ATryn [package insert] Framingham, MA: rEVO Biologics, December 2013.

Indications and Usage

ATryn is a recombinant antithrombin indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.


Important Safety Information

ATryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins. Allergic-type hypersensitivity reactions, including anaphylaxis, are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately and emergency treatment should be administered.

The anticoagulant effect of drugs that use antithrombin to exert their anticoagulation may be altered when ATryn is added or withdrawn. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. Additionally, patients should be monitored for the occurrence of bleeding or thrombosis in such situations.

The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of
≥ 5% are hemorrhage and infusion site reaction.

For more information, please view full Prescribing Information for ATryn.

To report suspected adverse reactions contact rEVO Biologics at 800-610-3776 or the FDA at 800-FDA-1088 or

For more information, please see full Prescribing Information for ATryn.

® ATryn is a registered trademark of rEVO Biologics, Inc.
rEVO Biologics is a registered trademark of LFB S.A.

link to

For medical inquiries, please
call 800-610-3776
or e-mail